Sugi Predict

Sugi Predict / Compounds / SCHEMBL3608462

SCHEMBL3608462

SCHEMBL3608462

CC(=O)[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.68
▸ ALDH1A1 P00352 1/20 0.68
▸ MAPT P10636 1/20 0.68
▸ KMT2A Q03164 1/20 0.68
▸ HPGD P15428 1/20 0.59
▸ EPHX1 P07099 1/20 0.49
▸ RECQL P46063 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSD11B1 P28845 1/20 0.43
▸ PREP P48147 1/20 0.43
▸ GLS O94925 1/20 0.43
▸ USP30 Q70CQ3 1/20 0.43
▸ NR1H2 P55055 1/20 0.42
▸ BACE1 P56817 2/20 0.42
▸ CTSD P07339 1/20 0.42
▸ PTPN2 P17706 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321211 1.00 MEN1 (0.68) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL2728409 1.00 MEN1 (0.68) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL21954154 0.95 MEN1 (0.63) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL845563 0.90 HPGD (0.62) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL13804048 0.90 HPGD (0.62) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL10233234 0.90 HPGD (0.62) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL27709430 0.89 MEN1 (0.66) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL28097167 0.89 MEN1 (0.66) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL24011078 0.88 ALDH1A1 (0.54) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL25596826 0.88 MEN1 (0.61) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118147098-B Leucine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis 江南大学 2025-04-25 — — CN disclosed
CN-118147098-A Leucine amine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis 江南大学 2024-06-07 — — CN disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
US-9758487-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-12 — — US disclosed
US-20160311778-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2016-10-27 — — US disclosed
US-9421192-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-23 — — US disclosed
US-20160067223-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-03-10 — — US disclosed
US-8900566-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-02 — — US disclosed
US-8846023-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
US-20140050695-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-02-20 — — US disclosed
US-8303944-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-06 — — US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 — — EP disclosed
US-20100158862-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 — — US disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 — — US disclosed
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-12 — — US disclosed
EP-1966139-A1 ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2008-09-10 — — EP disclosed
US-20080050336-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-28 — — US disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 — — WO disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 MEN1 2467/4885ALDH1A1 1416/4885MAPT 470/4885
US-20160067223-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20080050336-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20160311778-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20100158862-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885
US-20140050695-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MEN1 4867/4885ALDH1A1 1144/4885MAPT 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.